An overview of international initiatives in the regulatory sphere

Similar documents
US FDA and International Regulatory Efforts in Cellular and Gene Therapies

Medical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.

EU Update on Regulatory Developments

Work plan for the GMP/GDP Inspectors Working Group for 2017

Five years as EMA Liaison at US FDA

ROLE OF RELIANCE, RE-ENGINEERING, AND REGIONALIZATION IN THE OPTIMIZATION OF REGULATORY SYSTEMS

Medical Device Single Audit Program (MDSAP)

EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP)

FIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

Section I: Pharmaceuticals and Medical Devices

OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET

5 Countries. 1 Unified Audit.

Your Vision, Our Future Korean Medical Device Your Vision, Our Future

HARMONIZATION PROCESS FOR MEDICINES REGULATION IN THE SADC REGION MANDISA HELA HELA ON ON BEHALF OF SADC SADC SECRETARIAT GABORONE, BOTSWANA

MDSAP Me M dical D e D vice S i S ngle Audit Program

Biosimilar medicines rising to the cost challenge

Global Biologics Regulatory Trends Challenges and Opportunities..

Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)

WHO standards for regulatory evaluation of vaccines and biotherapeutic products current status and way forward

Medicines Control Council & update on SA Health Products Regulatory Authority

Updates. APEC Life Science and Innovation Forum Regulatory Harmonization Steering Committee (APEC LSIF-RHSC) NHA TRANG VIET NAM, FEBRUARY, 2017

Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments

COPING WITH INCREASING NEEDS FOR INSPECTIONS: ASEAN INITIATIVES. Abida Syed M Haq Ministry of Health, Malaysia

Brazilian Health Surveillance Agency - Anvisa & Brazilian Pharmacopoeia Global Regulatory Harmonization Opportunities

CANADA (HEALTH CANADA)

2. PMDA provides training program to officials from Thai FDA, Thailand (May 26 to 30)

Regulatory system strengthening

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Capacity Building Assistance: Moral Imperative or Common Sense?

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

REGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)

1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States

Brexit Guidance for Stakeholders Human and veterinary medicines

Global Medical Device QA/RA Consulting

An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America

E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES

VETERINARY DRUGS DIRECTORATE HEALTH PRODUCTS AND FOOD BRANCH HEALTH CANADA STRATEGIC PLAN

Veterinary Medicines Legislation and Maximum Residue Limits in the EU

How to support regulatory capacity strengthening in Sub-Saharan Africa EMA Perspective

Impact of WHO Guidelines on GMP for Blood Establishments

Clinical Trials application process, legislation & guidelines

SPECIAL EDITION. the backbone of clinical development

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document

Explanatory note on general fees payable to the European Medicines Agency

Progress Report on Recommendations of 14 th International Conference of Drug Regulatory Authorities (ICDRA) from WHO South-East Asia Region (SEAR)

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA

VICH Topic GL32 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: DEVELOPMENTAL TOXICITY TESTING

In the huge expanse of Asia, Singapore and

Good regulatory practices: guidelines for national regulatory authorities for medical products

A Study of procedures for Dossier Preparation and their marketing authorisation in different countries of selected drug(s)

REGULATORY COMPLIANCE } 19

Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan

Medical Device Single Audit Program (MDSAP) Key Points

CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH):

Comparison of medicines legislation in the East African Community

Collaboration: GS1 and Joint Initiative Council (JIC) in Healthcare

INFORMATION ON JAPANESE REGULATORY AFFAIRS

Questions And Answers To Support The

Introductions and Perspectives on International Harmonization

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Establishment of Clinical Trial Infrastructure

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets

WHO Prequalification Team (WHO-PQT) Introduction to medicines inspections technical updates

EU Perspective on Regulatory Issues for Biologics

APEC Occupational Standards Framework. Draft 1.2

Session 7 Clinical Trial Assessment Bioequivalence Studies

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

ABPI response to European Commission consultation on advanced therapy medicinal products

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Pharmaceuticals Sector Fiche ( )

AEO Mutual Recognition Arrangements/Agreements

Taking a Leap Toward Global Supply Chain Efficiency - Part II

OECD Recommendation on the Governance of Clinical Trials

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Strategy for the Emerging Markets Far East, Africa, Middle East, Latin America

A world in transition: PwC s 2017 APEC CEO Survey, November APEC CEO Survey. Indonesia findings.

RECENT TRENDS IN THE REGULATION OF BIOTECHNOLOGICAL PRODUCTS IN PERU

European Directorate for the Quality of Medicines & HealthCare (EDQM)

EDQM Conference. The European Pharmacopoeia Is it prepared for the future? Workshop 5. Workshop October 2010 Prague, Czech Republic

TRIPARTITE TRANSPORT AND TRANSIT FACILITATION PROGRAMME OVERVIEW OF THE PROGRAM

Good Distribution Practice and Supply Chain Risk Evaluation

Supporting Innovation through Scientific Advice

APEC Import MRL Guideline for Pesticides - enhancing trade, regulatory convergence and consumer protection.

Editor : Francoise SCHLEMMER Date : 09/03/2015 IMDRF, March 9 th 2015 REPORT Present : Hans-Heiner Junker Francoise SCHLEMMER

Summary of the work programme for the. European Medicines Agency

MEDICAL DEVICE GUIDANCE

CHAPTER 3 Drug Development

An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen

The European Medicines Agency: a model of patient/consumer interaction

Your Prestigious Partner to reach your business objectives

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

TransCelerate s Clinical Quality Management System: From a Vision to a Conceptual Framework

Strengthening Medical Device Regulatory Capacity in the Americas: working towards regulatory convergence. Alexandre Lemgruber

List of participants to the. WHO Chemical Risk Assessment Network

White Paper: Improvements to the Australian Regulatory System for Medical Devices. 23 May 2014

Transcription:

The place of the Certification Procedure in the global regulatory environment 19/20 September 2017, Prague, Czech Republic An overview of international initiatives in the regulatory sphere Cordula Landgraf Head of Networking, Swissmedic Do you know what substance this is? 2

Oxytocin an elixir to support cooperation? What recent studies suggest Increase of attention to social stimuli Reduction of natural fear of the other Promotion of getting closer to others and let us enjoy this closeness Cortisol Last but not least: promotion of building trust and establishing confidence Research by Markus Heinrichs and Ernst Fehr, University of Zurich 3 Nobody can do everything alone: An overview of international initiatives in the regulatory sphere 4

Outline 1. Background 2. Examples of initiatives 3. Latest developments and achievements Focus on IPRF and ICH 4. Summary & Outlook 5 Harmonisation versus Convergence Harmonisation of technical requirements for medicines regulation, i.e. legislation, guidelines, procedures, etc. (WHO) The process by which the interpretation and/or application of technical guidelines can be made uniform or mutually compatible. (FDA/CBER) Regulatory requirements become more similar or aligned over time as a result of gradual adoption of internationally recognised technical guidance documents and standards Does not represent harmonization of laws and regulations (APEC) 6

Reliance State of being dependent upon or confident in something or someone Having trust (The Business Dictionary) and Work Sharing Making use of work products and leveraging resources and expertise of as well as sharing workload between agencies. This includes: Reliance on or consideration of work already performed by other agencies Real-time work sharing for simultaneous activities ( joint assessments ). (ACSS Consortium) 7 Levels of regulatory cooperation Recognition Treaty Reliance/work sharing Based on treaties; «maximal benefit» but partial loss of sovereignty with regard to decision-making Benefit for regulators; sharing of workload, but independent decisions Trust Confidence building/harmonisation/ convergence «Foundation», Equivalence of requirements 8

Levels of regulatory cooperation Recognition Examples: Mutual Recognition Agreements (EU, ASEAN); marketing authorisation procedures (EU, GCC); unilateral recognition of marketing authorisations (Mexico); Reliance/Work-sharing Examples: Abridged application routes/reference country model; WHO Pre- Qualification; EAC/MRH joint assessment procedure; ZAZIBONA(S), IGDRP; ACSS Consortium (HSA, TGA, HPFB, Swissmedic); Confidence building/harmonisation/convergence Examples: AMRH; EAC/MRH; PIC/S; ICH; IPRF; IGDRP; IMDRF; RHIs/RECs; WHO trainings and networks, ICDRA; GRPs; Bilateral agreements; 9 Outline 1. Background 2. Examples of initiatives 3. Latest developments and achievements 4. Summary 10

Examples of global initiatives involved in convergence/harmonisation (1) Initiative Scope Main objective(s)/areas of work ICH www.ich.org VICH www.i-p-rf.org IGDRP www.i-p-rf.org IPRF www.i-p-rf.org Human medicinal products Veterinary medicinal products Generics Medicinal products Harmonisation of requirements for registration for human medicinal products Harmonisation of requirements for registration for veterinary medicinal products Promote collaboration and convergence in generic drug regulatory programs in order to address the challenges posed by increasing workloads, globalisation and complexity of scientific issues Support implementation of ICH and other internationally harmonized technical guidelines; identification of need for harmonization or convergence in specific areas; 11 Examples of global initiatives involved in convergence/harmonisation (2) Initiative Scope Main objective(s)/areas of work IMDRF www.imdrf.org WHO www.who.int PIC/S www.picschem e.org ICMRA http://www.icm ra.info/ Medical Devices Health Products GMP inspections Medicinal products Accelerate international medical device regulatory harmonization and convergence Development of international standards for the manufacturing and regulation of health products Developing and promoting harmonised GMP standards and guidance documents... Regulatory convergence, alignment and standards development; regulatory cooperation and worksharing; capacity and competence building/technical assistance; regulatory systems comparability criteria and assessment criteria; regulatory science. 12

Examples of global initiatives involved in convergence/harmonisation (3) Initiative Scope Main objective(s)/areas of work WHO Prequalification http://www.who.int/topic s/prequalification/en/ EAC MRH Joint Assessment Procedure, ZAZIBONA, other RECs http://mrh.eac.int/; http://www.mcaz.co.zw/i ndex.php ACSS Consortium Drugs, vaccines, diagnostics Medicinal products Medicinal products/ medical devices The prequalification process consists of a transparent, scientifically sound assessment, which includes dossier review, consistency testing or performance evaluation and site visits to manufacturers. Work-sharing in the marketing authorisation of medicinal products, supported by WHO and stringent regulatory authorities Various collaborative projects ranging from marketing authorisation, post-market surveillance to IT. Outline 1. Background 2. Examples of initiatives 3. Latest developments and achievements Focus on ICH and IPRF 4. Summary 14

ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Established as a legal entity (international association based in Geneva, CH) Bodies of the association 15 Altogether: ICH Members 14 Opening up to new members and observers Observers 23 New regulatory members: Agência Nacional de Vigilância Sanitária (ANVISA), Brasil CFDA, China MFDS, South Korea Current observers include: Southern African Development Community (SADC) Gulf Cooperation Council (GCC) Pan American Network for Drug Regulatory Harmonization (PANDRH) Asia-Pacific Economic Cooperation (APEC) Therapeutic Goods Administration (TGA) http://www.ich.org/about/membership.html 16

ICH ICH Assembly Meeting, Montréal, Canada, May/June 2017 Adoption of two new ICH topics Guideline on extrapolation of paediatric indications E8(R1) General considerations for clinical trials as part of the announced GCP renovation (http://www.ich.org/products/gcp-renovation.html) 17 IPRF The IPRF has emerged from the Regulators Forum in 2013 Regulators-only platform, meeting twice a year in the margins of the ICH week Membership quite extensive Australia (TGA) Brazil (ANVISA) EU (EMA/EU Commission) Canada (Health Canada) Japan (MHLW/PMDA) Korea (MFDS) Mexico (Cofepris) Russia (Roszdravnadzor) Singapore (HSA) Switzerland (Swissmedic) USA (FDA) RHIs WHO (observer) https://www.i-p-r-f.org/index.php/en/members/ 18

IPRF The Management Committee (MC) currently oversees the work of five working groups: Cell Therapy Gene Therapy Biosimilars Nanomedicines IDMP 19 IPRF Biosimilars Working Group Development of a template for Public Assessment Summary Information for Biosimilar (PASIB) Development of a Reflection paper on extrapolation of indications for biosimilars to be published soon on the IPRF website The Biosimilars Working Group has held a workshop with WHO to advance work on developing training material to establish biosimilar comparability 20

IPRF / IGDRP consolidation Principle support by both the IPRF Management Committee and the IGDRP Steering Committee Establishment of a joint Implementation Task Group (ITG) to consider various governance models for the joint initiative and to work out an implementation plan Joint initiative expected to be launched in January 2018 First joint f2f meeting planned for June 2018 21 Outline 1. Background 2. Examples of initiatives 3. Latest developments and achievements 4. Summary & Outlook 22

Summary Initiatives with the focus on harmonisation/convergence are well under way Increasing participation from regulators in multilateral/ global initiatives Consolidation of initiatives has started to avoid overlap and duplication (IPRF/IGDRP) 23 Summary Increasing number of initiatives focussing on reliance and work sharing even the largest agencies cannot do everything themselves Reliance accepted in the developed world (e.g. GMP inspections, sharing of assessment reports) WHO increasingly and successfully promotes reliance and work sharing models in developing countries 24

Interested to read more? See our article Swissmedic emphazises international cooperation https://www.swissmedic.ch/ueber/01398/01401/index.html?lang=en Questions? Contact Information Cordula Landgraf Head of Networking Swissmedic Tel.: +41 58 462 0478 E-mail: networking@swissmedic.ch

List of Abbreviations ACSS Australia-Canada-Singapore-Switzerland ( Consortium ) AMRH African Medicines Regulatory Harmonisation ANVISA Brazilian Health Surveillance Agency APEC Asia-Pacific Economic Cooperation ASEAN Association of Southeast Asian Nations BfArM Federal Institute for Drugs and Medical Devices BMGF Bill & Melinda Gates Foundation CBER Centre for Biologics Evaluation and Research CFDA China Food and Drug Administration EAC East African Community EAC MRH EAC Medicines Regulatory Harmonisation EDQM European Directorate for the Quality of Medicines and Healthcare EMA European Medicines Agency EU European Union GCC Gulf Cooperation Council GRP Good Regulatory Practices HPFB Health Products and Food Branch HPRA Health Products Regulatory Authority HSA Health Sciences Authority ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICDRA International Conference of Drug Regulatory Authorities ICMRA International Coalition of Medicines Regulatory Authorities IDMP Identification of a Medicinal Product IPRF International Pharmaceutical Regulators Forum IGDRP International Generic Drug Regulators Programme IMDRF International Medical Device Regulators Forum MCC Medicines Control Council, has transitioned into the South African Health Products Regulatory Authority MFDS Ministry of Food and Drug Safety MHLW Ministry of Health, Labour and Welfare MOH Ministry of Health MoU Memorandum of Understanding OECD Organisation for Economic Co-operation and Development PANDRH Pan-American Network for Regulatory Harmonisation PEI Paul Ehrlich Institute PIC/S Pharmaceutical Inspections Cooperation Scheme PMDA Pharmaceuticals and Medical Devices Agency REC Regional Economic Community RHI Regional Harmonisation Initiative TGA Therapeutic Goods Administration US-FDA United States Food and Drug Administration VICH International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products WHO World Health Organisation ZAZIBONA Zambia-Zimbabwe-Botswana-Namibia (Collaborative medicines registration process)